Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine

Vaccine ◽  
1999 ◽  
Vol 17 (5) ◽  
pp. 454-458 ◽  
Author(s):  
Charlotte Larsson ◽  
Margaretha Stålhammar-Carlemalm ◽  
Gunnar Lindahl
Keyword(s):  
Experimental Infection ◽  
Group B Streptococcus ◽  
Protein Vaccine ◽  
Group B

scholarly journals Group B Streptococcal Colonization in African Countries: Prevalence, Capsular Serotypes, and Molecular Sequence Types

Pathogens ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1606
Author(s):  
Sarah Shabayek ◽  
Patricia Ferrieri ◽  
Barbara Spellerberg
Keyword(s):  
Group B Streptococcus ◽  
Epidemiological Data ◽  
Protein Vaccine ◽  
African Countries ◽  
Suitable Alternative ◽  
Promising Alternative ◽  
Molecular Sequence ◽  
Resource Limited ◽  
Group B ◽  
Sequence Types

Streptococcus agalactiae or group B streptococcus (GBS) is a commensal of the gastrointestinal and genitourinary tracts of healthy women and an important cause of neonatal invasive infections worldwide. Transmission of bacteria to the newborn occurs at birth and can be prevented by intrapartum antibiotic prophylaxis. However, this not available in resource limited settings in Africa, which carries a particular high burden of disease. Serotype based vaccines are in development and present a suitable alternative to prevent neonatal infections. To be able to assess vaccine efficacy, knowledge and surveillance of GBS epidemiological data are required. This review summarizes investigations about the serotype distribution and the multi-locus sequence types (MLST) found in different African countries. While most serotypes and MLST data are comparable to findings from other continents, some specific differences exist. Serotype V is predominant among colonizing maternal strains in many different African countries. Serotypes that are rarely detected in western industrialized nations, such as serotypes VI, VII and IX, are prevalent in studies from Ghana and Egypt. Moreover, some specific MLST sequence types that seem to be more or less unique to Africa have been detected. However, overall, the data confirm that a hexavalent vaccine can provide broad coverage for the African continent and that a protein vaccine could represent a promising alternative.

scholarly journals Molecular Characteristics of IS 1216 Carrying Multidrug Resistance Gene Cluster in Serotype III/Sequence Type 19 Group B Streptococcus

mSphere ◽  
2021 ◽  
Author(s):  
Yong Zhi ◽  
Hyun Jung Ji ◽  
Jong Hyun Jung ◽  
Eui Baek Byun ◽  
Woo Sik Kim ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Bacterial Colonization ◽  
Group B Streptococcus ◽  
Sequence Type ◽  
Molecular Characteristics ◽  
Protein Vaccine ◽  
Multidrug Resistance Gene ◽  
Content Type ◽  
Vaccine Candidates ◽  
Group B

Most previously isolated group B streptococcus (GBS) strains express either the Srr1 or Srr2 glycoprotein, which plays an important role in bacterial colonization and invasion. These glycoproteins are potential protein vaccine candidates.

scholarly journals Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies.

1983 ◽  
Vol 158 (3) ◽  
pp. 1006-1011 ◽  
Author(s):  
M L Egan ◽  
D G Pritchard ◽  
H C Dillon ◽  
B M Gray
Keyword(s):  
Monoclonal Antibodies ◽  
Experimental Infection ◽  
Group B Streptococcus ◽  
Antigenic Determinants ◽  
Group B Streptococci ◽  
Lethal Challenge ◽  
Type Iii ◽  
Group B

Mouse hybridoma antibodies of several major classes against group B streptococcus type III have been produced. Mice were immunized with either whole heat-killed or acid-treated organisms to obtain antibodies against both the complete (sialated) or incomplete (nonsialated) forms of the type III polysaccharide. Resulting monoclonal antibodies showed exclusive specificity for either the complete or incomplete antigen. The ability of these antibodies to protect mice from a lethal challenge of live type III organisms was tested with a mucin model that permitted use of very small inocula given intraperitoneally with antibody and mucin. Antibodies specific for the nonsialated antigen were not protective, whether of IgM, IgG2a, or IgG3 isotypes. Antibodies specific for the complete antigen were, however, highly protective, including monoclonals of IgM, IgG2a, and IgA isotypes. These mouse monoclonal antibodies against group B streptococci that are directed against either complete or incomplete antigenic determinants, and include isotypes other than IgM, should be particularly useful for studying the mechanism of protection against experimental infection.

Sign in / Sign up

Export Citation Format

Share Document